Exploring Morbidity and Mortality in Psoriatic Arthritis Patients on Immunotherapy

This chapter examines the connection between psoriatic arthritis and the heightened risk of autoimmune adverse events, especially concerning mortality rates associated with immunotherapy. It highlights the varying risks linked to different immunotherapy agents and underscores the significance of this understanding as checkpoint inhibitors gain prevalence in cancer treatment.